IMMUCELL CORP (ICCC) Stock Price, Quote, News and Overview
NASDAQ:ICCC - Nasdaq - US4525253062 - Common Stock - Currency: USD
ICCC Quote, Performance and Key Statistics
NASDAQ:ICCC (2/21/2025, 8:27:27 PM)
5.02
+0.01 (+0.2%)
The current stock price of ICCC is 5.02 USD. In the past month the price decreased by -8.39%. In the past year, price decreased by -2.33%.
ICCC Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About ICCC
Company Profile
ImmuCell Corp. engages in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company is headquartered in Portland, Maine and currently employs 74 full-time employees. The firm is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. The company operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing Immediate Immunity against each of the three causes of calf scours (E. coli, coronavirus, and rotavirus).
Company Info
IMMUCELL CORP
56 Evergreen Drive
Portland MAINE 04103 US
CEO: Michael F. Brigham
Employees: 78
Company Website: https://immucell.com/
Investor Relations: http://immucell.com/quick-facts-corporate-governance/
Phone: 12078782770
IMMUCELL CORP / ICCC FAQ
What is the stock price of IMMUCELL CORP today?
The current stock price of ICCC is 5.02 USD. The price increased by 0.2% in the last trading session.
What is the ticker symbol for IMMUCELL CORP stock?
The exchange symbol of IMMUCELL CORP is ICCC and it is listed on the Nasdaq exchange.
On which exchange is ICCC stock listed?
ICCC stock is listed on the Nasdaq exchange.
What is IMMUCELL CORP worth?
IMMUCELL CORP (ICCC) has a market capitalization of 44.73M USD. This makes ICCC a Nano Cap stock.
How many employees does IMMUCELL CORP have?
IMMUCELL CORP (ICCC) currently has 78 employees.
What are the support and resistance levels for IMMUCELL CORP (ICCC) stock?
IMMUCELL CORP (ICCC) has a support level at 5.01 and a resistance level at 5.02. Check the full technical report for a detailed analysis of ICCC support and resistance levels.
Should I buy IMMUCELL CORP (ICCC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ICCC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ICCC, evaluating the profitability, health, valuation and growth aspects
- IMMUCELL CORP (ICCC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- IMMUCELL CORP (ICCC) Sales and EPS estimates to see what analysts future expectations are.
- IMMUCELL CORP (ICCC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- IMMUCELL CORP (ICCC) Insider and Institutional Ownership to learn about the owners and their transactions.
- IMMUCELL CORP (ICCC) Stock Chart to make your own analysis
- IMMUCELL CORP (ICCC) Latest news and press-releases to stay up to date.
Does IMMUCELL CORP (ICCC) stock pay dividends?
ICCC does not pay a dividend.
When does IMMUCELL CORP (ICCC) report earnings?
IMMUCELL CORP (ICCC) will report earnings on 2025-02-25, after the market close.
What is the Price/Earnings (PE) ratio of IMMUCELL CORP (ICCC)?
IMMUCELL CORP (ICCC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.5).
What is the Short Interest ratio of IMMUCELL CORP (ICCC) stock?
The outstanding short interest for IMMUCELL CORP (ICCC) is 0.27% of its float. Check the ownership tab for more information on the ICCC short interest.
ICCC Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ICCC. When comparing the yearly performance of all stocks, ICCC is one of the better performing stocks in the market, outperforming 83.95% of all stocks.
ICCC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ICCC. ICCC may be in some trouble as it scores bad on both profitability and health.
ICCC Financial Highlights
Over the last trailing twelve months ICCC reported a non-GAAP Earnings per Share(EPS) of -0.5. The EPS increased by 39.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.57% | ||
| ROE | -14.43% | ||
| Debt/Equity | 0.36 |
ICCC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to ICCC. The Buy consensus is the average rating of analysts ratings from 7 analysts.